Bremelanotide (PT‑141): MC4R agonism and RECONNECT

Bremelanotide, developed under the code name PT-141, is a synthetic melanocortin receptor agonist. It descends from the melanotan II research programme and became a licensed medicine in the United States for a specific form of low sexual desire in premenopausal women. This article reviews its receptor pharmacology, its development, the RECONNECT phase 3 trials and its adverse-event profile. It also explains why the licensed medicine is not the same thing as unregulated material sold under the name PT-141.

This article summarises published research for scientific understanding. It is not prescribing guidance and does not describe or endorse personal use.

The melanocortin system and MC4R

Melanocortins act on five receptors, MC1R to MC5R, which regulate pigmentation, adrenal steroid production, energy balance and erectile responses, among other functions^[1]. Four of the five, MC1R and MC3R to MC5R, recognise α-melanocyte-stimulating hormone (α-MSH) and its potent synthetic analogues^[2].

Bremelanotide activates several melanocortin receptor subtypes without strong selectivity. Of these, MC4R is considered the most relevant at therapeutic doses. MC4R is expressed prominently in the medial preoptic area of the hypothalamus, a region important for female sexual function. Animal studies suggest that bremelanotide may act there on presynaptic MC4R to increase the release of dopamine, an excitatory neurotransmitter associated with sexual desire^[3]. That proposed mechanism rests mainly on animal work.

Human mechanistic evidence comes from a randomised, double-blind, placebo-controlled crossover study in 31 premenopausal women with hypoactive sexual desire disorder (HSDD). MC4R agonism increased self-reported sexual desire for up to 24 hours compared with placebo. On functional brain imaging, it altered activity in several brain regions specifically in response to erotic stimuli^[4]. The authors interpreted the pattern as reduced self-consciousness and greater sensitivity to erotic cues. That interpretation is an inference from imaging, not a direct measurement.

From melanotan II to bremelanotide

Bremelanotide's origins lie in the Arizona research programme that produced melanotan I and melanotan II. Melanotan II was studied in the 1990s in men with erectile dysfunction, and PT-141 was developed from it by Palatin Technologies^[5]. Our melanotan II review covers those earlier studies and the safety signals linked to unregulated melanotan use.

Early development used a nasal formulation. By 2007, bremelanotide was described as the only melanocortin agent studied clinically in both men and women. Phase II data supported further work in erectile dysfunction, and preliminary data suggested effects on desire and arousal in women^[6]. Development later focused on women and on an injected formulation. Palatin sponsored the phase 3 trials, and North American rights were licensed to another company for regulatory submission^[7].

The relationship to melanotan II explains a shared pharmacology, but not interchangeability. The two are distinct compounds, and bremelanotide went through a separate clinical development programme.

The clinical programme

RECONNECT: design and endpoints

The two RECONNECT trials enrolled premenopausal women with HSDD and randomised them equally to bremelanotide or placebo, used as needed for 24 weeks. There were two co-primary endpoints: the desire domain of the Female Sexual Function Index, and an item from the Female Sexual Distress Scale measuring distress related to low desire. Most participants were white (85.6%) and from US sites (96.6%), with a mean age of 39 years^[10].

Both trials met both endpoints. In the integrated analysis, the desire score improved by 0.35 points more than with placebo, and the distress score fell by 0.33 points more^[10]. These differences were statistically significant. A later review noted that, although the trials met statistical significance, the clinical benefit may be modest^[12]. Whether a statistically significant difference on a questionnaire is meaningful to an individual is a separate question from whether it is real.

Adverse-event reporting

Across the phase 3 programme, the most common adverse events were nausea, flushing and headache.

These figures come from the integrated double-blind portion of the phase 3 studies, involving 1,247 women^[13]. Nausea was the most common reason for stopping treatment. In the same programme, 70% of the bremelanotide group continued into the open-label phase, compared with 87% of the placebo group^[13].

Two further findings are relevant to safety:

• Blood pressure. Ambulatory monitoring detected small, transient rises in systolic blood pressure of around 2 to 3 mmHg after dosing, accompanied by reductions in heart rate. Peak increases usually lasted less than 15 minutes^[9]. The integrated safety review recommended caution in people at risk of cardiovascular disease^[13].
• Focal hyperpigmentation. Darkening of areas of skin was rare with use as labelled. It occurred in more than a third of participants given up to 16 consecutive daily doses^[13]. This is consistent with the compound's activity at melanocortin receptors involved in pigmentation.

Regulatory context

Bremelanotide was approved in the United States in 2019 for premenopausal women with acquired, generalised HSDD, defined as low sexual desire causing marked distress or interpersonal difficulty^[7]. At the time of writing, the US Food and Drug Administration's Drugs@FDA database listed it as a prescription product under its original 2019 approval. This article makes no claim about its regulatory status in the United Kingdom or elsewhere.

The licensed medicine and "PT-141" research materials

The evidence described above concerns a licensed pharmaceutical product. It was manufactured under regulatory controls, tested in defined populations and supplied in a specified formulation. Material sold outside regulated supply chains under the name "PT-141" is a different matter. Its identity, purity and content are not established by the name on the label. One analytical study found that a peptide purchased for research from one of five manufacturers was a different peptide altogether^[14]. The clinical trial results for bremelanotide cannot be assumed to apply to such materials. Our article on reading a certificate of analysis discusses what analytical documentation can and cannot establish.

Limitations of the evidence

• Narrow population. The phase 3 participants were premenopausal women, mostly white and almost all recruited in the United States^[10]. The results do not describe postmenopausal women, men or other populations.
• Modest effect sizes. The differences from placebo were statistically significant but small on the scales used^[10][12].
• Uncontrolled long-term data. The 52-week extension was open-label and descriptive, and fewer than half of those who entered completed it^[11].
• Industry sponsorship. The phase 3 trials were sponsored by the developer^[7].
• Mechanism. The proposed dopamine mechanism is based largely on animal work^[3].

Summary

Bremelanotide is a non-selective melanocortin receptor agonist, with MC4R considered most relevant to its effects on sexual desire. It was developed from melanotan II, but it is a distinct compound with its own clinical programme. The two RECONNECT trials showed statistically significant but modest improvements in desire and related distress in premenopausal women with HSDD. Nausea was common and was the main reason for stopping treatment, and there were small, transient rises in blood pressure. Bremelanotide is a licensed prescription medicine in the United States. Its evidence applies to that product in the populations studied, not to unregulated materials sold under the name PT-141.